TY - JOUR T1 - What Have We Learned? Implementation of a Shared Learning Agenda and Access Strategy for the Hormonal Intrauterine Device JF - Global Health: Science and Practice JO - GLOB HEALTH SCI PRACT DO - 10.9745/GHSP-D-21-00789 VL - 10 IS - 5 SP - e2100789 AU - Kate H. Rademacher AU - Tabitha Sripipatana AU - Kendal Danna AU - Deborah Sitrin AU - Aurélie Brunie AU - Katie M. Williams AU - Kayode Afolabi AU - Francia Rasoanirina AU - Saumya Ramarao AU - Anne Pfitzer AU - Devon Cain AU - Morgan Simon AU - Elaine Menotti AU - Anna Hazelwood AU - Anthony Adindu Nwala AU - Zainab Saidu AU - Raveena Chowdhury AU - Anne Taiwo AU - Agnes Chidanyika AU - Gathari Ndirangu AU - Markus J. Steiner AU - Marie Chantale Lepine AU - Rick Homan AU - Abdulmumin Saad AU - John Vivalo AU - Laneta J. Dorflinger Y1 - 2022/10/31 UR - http://www.ghspjournal.org/content/10/5/e2100789.abstract N2 - Key FindingsIn this review of early experiences providing the hormonal intrauterine device (IUD) in sub-Saharan Africa, we found: Continuation and satisfaction were high among hormonal IUD users in pilot settings and generally comparable to those of other long-acting reversible contraceptives.Hormonal IUD users reported positive attributes of the method including its effectiveness, long duration, convenience, potential for reduced bleeding, and fewer side effects compared to other hormonal methods.Coordination across diverse organizations, including alignment on a shared learning agenda and access strategy, ultimately contributed to expanded access to the method.Key ImplicationsAs several countries in sub-Saharan Africa are preparing to introduce the hormonal IUD on a wider scale, the addition of the hormonal IUD to the catalogs of the United States Agency for International Development and the United Nations Population Fund will help expand public-sector access.Additional investments in method introduction—including provider training, demand creation, robust implementation research, and monitoring and evaluation—will be critical to understanding how best to scale the method.In 2015, a global learning agenda for the hormonal intrauterine device (IUD) was developed with priority research questions regarding use of the method in low- and middle-income countries. In addition, members of the Hormonal IUD Access Group aligned on a strategy to expand access in the context of volunteerism and contraceptive method choice. This article synthesizes evidence generated since then and describes steps taken to address demand- and supply-side barriers to access. Findings demonstrated high continuation rates and satisfaction among hormonal IUD users that are comparable to other long-acting reversible contraceptives (LARCs). Across studies, a sizable number of users reported they would have chosen a short-acting method or no method at all if the hormonal IUD were not an option, which suggests that women did not see the hormonal IUD as interchangeable with other LARC options and thus it may fill an important niche in the market. With several countries now poised to scale up the method, resource mobilization will be key. On the demand side, investments in implementation research will be critical to understanding how best to launch and scale the method, while ensuring the sustainability of multiple quality-assured suppliers with affordable public-sector pricing will be necessary on the supply side. ER -